|
Gene: TG |
Gene summary for TG |
Gene summary. |
Gene information | Species | Human | Gene symbol | TG | Gene ID | 7038 |
Gene name | thyroglobulin | |
Gene Alias | AITD3 | |
Cytomap | 8q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006575 | UniProtAcc | P01266 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7038 | TG | Adj_PTCwithHT_6 | Human | Thyroid | HT | 7.30e-105 | -2.11e+00 | 0.02 |
7038 | TG | Adj_PTCwithHT_8 | Human | Thyroid | HT | 6.03e-06 | -2.18e-01 | 0.0267 |
7038 | TG | PTCwithHT_1 | Human | Thyroid | HT | 1.56e-31 | -1.52e+00 | 0.0238 |
7038 | TG | PTCwithHT_6 | Human | Thyroid | HT | 1.38e-104 | -2.12e+00 | 0.02 |
7038 | TG | PTCwithHT_8 | Human | Thyroid | HT | 2.54e-58 | -1.07e+00 | 0.0351 |
7038 | TG | PTCwithoutHT_2 | Human | Thyroid | PTC | 3.80e-11 | -3.56e-01 | 0.0419 |
7038 | TG | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.95e-19 | -8.43e-01 | 0.0381 |
7038 | TG | male-WTA | Human | Thyroid | PTC | 1.56e-05 | 1.85e-01 | 0.1037 |
7038 | TG | nodule-WTA | Human | Thyroid | goiters | 1.11e-15 | 2.90e-01 | 0.0534 |
7038 | TG | PTC01 | Human | Thyroid | PTC | 1.01e-25 | 2.49e+00 | 0.1899 |
7038 | TG | PTC03 | Human | Thyroid | PTC | 2.57e-11 | 1.84e+00 | 0.1784 |
7038 | TG | PTC04 | Human | Thyroid | PTC | 7.44e-08 | 1.70e+00 | 0.1927 |
7038 | TG | PTC05 | Human | Thyroid | PTC | 7.32e-32 | 2.88e+00 | 0.2065 |
7038 | TG | PTC06 | Human | Thyroid | PTC | 8.06e-54 | 4.16e+00 | 0.2057 |
7038 | TG | PTC07 | Human | Thyroid | PTC | 5.54e-48 | 2.79e+00 | 0.2044 |
7038 | TG | ATC08 | Human | Thyroid | ATC | 1.04e-55 | -1.49e+00 | 0.0541 |
7038 | TG | ATC09 | Human | Thyroid | ATC | 2.30e-54 | -2.31e+00 | 0.2871 |
7038 | TG | ATC11 | Human | Thyroid | ATC | 5.27e-20 | -2.31e+00 | 0.3386 |
7038 | TG | ATC12 | Human | Thyroid | ATC | 2.29e-129 | -2.31e+00 | 0.34 |
7038 | TG | ATC13 | Human | Thyroid | ATC | 7.68e-130 | -2.30e+00 | 0.34 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
GO:007259333 | Thyroid | ATC | reactive oxygen species metabolic process | 112/6293 | 239/18723 | 1.34e-05 | 1.28e-04 | 112 |
GO:003235519 | Thyroid | ATC | response to estradiol | 72/6293 | 141/18723 | 1.35e-05 | 1.29e-04 | 72 |
GO:001988229 | Thyroid | ATC | antigen processing and presentation | 57/6293 | 106/18723 | 1.48e-05 | 1.39e-04 | 57 |
GO:0030038111 | Thyroid | ATC | contractile actin filament bundle assembly | 57/6293 | 106/18723 | 1.48e-05 | 1.39e-04 | 57 |
GO:0043149111 | Thyroid | ATC | stress fiber assembly | 57/6293 | 106/18723 | 1.48e-05 | 1.39e-04 | 57 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
GO:007126022 | Thyroid | ATC | cellular response to mechanical stimulus | 46/6293 | 81/18723 | 1.51e-05 | 1.41e-04 | 46 |
GO:200102114 | Thyroid | ATC | negative regulation of response to DNA damage stimulus | 46/6293 | 81/18723 | 1.51e-05 | 1.41e-04 | 46 |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
GO:004440933 | Thyroid | ATC | entry into host | 76/6293 | 151/18723 | 1.54e-05 | 1.43e-04 | 76 |
GO:004639025 | Thyroid | ATC | ribose phosphate biosynthetic process | 92/6293 | 190/18723 | 1.57e-05 | 1.46e-04 | 92 |
GO:003361914 | Thyroid | ATC | membrane protein proteolysis | 35/6293 | 57/18723 | 1.58e-05 | 1.46e-04 | 35 |
GO:007217522 | Thyroid | ATC | epithelial tube formation | 68/6293 | 132/18723 | 1.59e-05 | 1.48e-04 | 68 |
GO:007190215 | Thyroid | ATC | positive regulation of protein serine/threonine kinase activity | 96/6293 | 200/18723 | 1.63e-05 | 1.51e-04 | 96 |
GO:0022612110 | Thyroid | ATC | gland morphogenesis | 62/6293 | 118/18723 | 1.68e-05 | 1.55e-04 | 62 |
GO:190118415 | Thyroid | ATC | regulation of ERBB signaling pathway | 45/6293 | 79/18723 | 1.68e-05 | 1.55e-04 | 45 |
GO:000920627 | Thyroid | ATC | purine ribonucleoside triphosphate biosynthetic process | 40/6293 | 68/18723 | 1.74e-05 | 1.59e-04 | 40 |
GO:003246925 | Thyroid | ATC | endoplasmic reticulum calcium ion homeostasis | 19/6293 | 25/18723 | 1.77e-05 | 1.62e-04 | 19 |
GO:004311224 | Thyroid | ATC | receptor metabolic process | 82/6293 | 166/18723 | 1.78e-05 | 1.63e-04 | 82 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
COL1A1 | ITGA1_ITGB1 | COL1A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA1_ITGB1 | COL4A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA1_ITGB1 | COL4A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA1_ITGB1 | COL6A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA1_ITGB1 | COL6A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA1_ITGB1 | COL6A3_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A1 | ITGA2_ITGB1 | COL1A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA2_ITGB1 | COL4A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA2_ITGB1 | COL4A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA2_ITGB1 | COL6A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA2_ITGB1 | COL6A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA2_ITGB1 | COL6A3_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
LAMA2 | ITGA1_ITGB1 | LAMA2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMA4 | ITGA1_ITGB1 | LAMA4_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB2 | ITGA1_ITGB1 | LAMB2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC1 | ITGA1_ITGB1 | LAMC1_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC2 | ITGA1_ITGB1 | LAMC2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
TG | SNV | Missense_Mutation | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TG | SNV | Missense_Mutation | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TG | SNV | Missense_Mutation | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
TG | SNV | Missense_Mutation | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIDS | 12182039 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | BISPECIFIC ANTIBODY | 10433080 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PHENYTOIN | PHENYTOIN | 3935423 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISONE | PREDNISONE | 2745931 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | ALL-TRANS-RETINOIC ACID | 10946899 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | TGFBETA1 | 10770487,10194419 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIC ACID | 11563543 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | AMIODARONE | AMIODARONE | 8778159 |
Page: 1 2 3 4 |